{"id":"huperzine-a-controlled-release-tablets","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Vomiting"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL394259","moleculeType":"Small molecule","molecularWeight":"242.32"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting acetylcholinesterase, Huperzine A prevents the breakdown of acetylcholine, a neurotransmitter involved in memory and cognitive function. This leads to increased acetylcholine levels, which can improve memory and cognitive performance. Huperzine A's mechanism is similar to that of donepezil, a commonly used Alzheimer's medication.","oneSentence":"Huperzine A is a reversible cholinesterase inhibitor that increases acetylcholine levels in the brain.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T04:01:13.857Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Alzheimer's disease"}]},"trialDetails":[{"nctId":"NCT07066826","phase":"PHASE2, PHASE3","title":"Clinical Study to Evaluate the Efficacy and Safety of Huperzine A Controlled-Release Tablets in Patients With Mild-to-Moderate Dementia of the Alzheimer's Type","status":"NOT_YET_RECRUITING","sponsor":"Wanbangde Pharmaceutical Group Co., LTD","startDate":"2025-08-01","conditions":"Alzheimer Dementia","enrollment":720},{"nctId":"NCT01282619","phase":"PHASE2, PHASE3","title":"Study of Huperzine A Sustained-Release Tablets in Patients With Alzheimer's Disease","status":"UNKNOWN","sponsor":"Shandong Luye Pharmaceutical Co., Ltd.","startDate":"2010-05","conditions":"Alzheimer's Disease","enrollment":390}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Huperzine A Controlled-Release Tablets","genericName":"Huperzine A Controlled-Release Tablets","companyName":"Wanbangde Pharmaceutical Group Co., LTD","companyId":"wanbangde-pharmaceutical-group-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Huperzine A is a reversible cholinesterase inhibitor that increases acetylcholine levels in the brain. Used for Alzheimer's disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}